Production (Stage)
Zealand Pharma A/S
ZLDPF
$62.36
$0.01560.03%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -84.05% | -81.87% | -77.78% | 317.54% | 235.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -84.05% | -81.87% | -77.78% | 317.54% | 235.77% |
| Cost of Revenue | -78.44% | -33.72% | 44,632.26% | 690.76% | -- |
| Gross Profit | -84.33% | -83.55% | -83.30% | 261.21% | 219.98% |
| SG&A Expenses | 74.49% | 86.58% | 53.44% | 27.56% | 4.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,528.12% | 101.14% | 137.93% | 78.96% | 78.96% |
| Total Operating Expenses | 46.90% | 47.10% | 33.28% | 29.95% | 15.83% |
| Operating Income | -116.74% | -126.46% | -102.72% | 4.04% | 14.16% |
| Income Before Tax | -58.30% | -52.90% | -39.77% | 26.74% | 28.79% |
| Income Tax Expenses | 4.17% | 9.81% | 21.96% | 27.23% | 31.11% |
| Earnings from Continuing Operations | -58.70% | -53.35% | -40.25% | 26.74% | 28.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.70% | -53.35% | -36.07% | 28.21% | 35.56% |
| EBIT | -116.74% | -126.46% | -102.72% | 4.04% | 14.16% |
| EBITDA | -122.12% | -139.76% | -110.64% | -1.04% | 12.02% |
| EPS Basic | -37.19% | -29.92% | -14.20% | 38.64% | 48.49% |
| Normalized Basic EPS | -77.40% | -72.54% | -40.03% | 29.14% | 46.70% |
| EPS Diluted | -36.75% | -29.50% | -13.88% | 38.42% | 48.33% |
| Normalized Diluted EPS | -76.73% | -71.87% | -39.59% | 28.91% | 46.50% |
| Average Basic Shares Outstanding | 16.16% | 17.40% | 18.29% | 19.34% | 25.68% |
| Average Diluted Shares Outstanding | 15.23% | 16.42% | 17.26% | 20.28% | 26.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |